cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.11926794
title: EEG datasets and metadata supporting the published article: Neural dynamics underlying coherent motion perception in children and adults

description: This fileset contains EEG data related to the following published article: Catherine Manning, Blair Kaneshiro, Peter J. Kohler, Mihaela Duta, Gaia Scerif and Anthony M. Norcia. (2019). Neural dynamics underlying coherent motion perception in children and adults. <i>Developmental Cognitive Neuroscience, 38, </i>100670 https://doi.org/10.1016/j.dcn.2019.100670<i>.</i> The script <b>MOVEP_analysis4_corrected.m</b> was used to generate the output .mat datasets contained in this data record. This code has already been shared under a BSD license on the OSF repository: https://osf.io/fkjt6/ (which is linked to in the published paper). A total of 122 Matlab formatted datasets are contained in this data record, each contains pre-processed electroencephalography (EEG) data for each of the 122 participants of the study. The datasets have the following format: <b>Formatted_XXXX.3_40_preproc.mat, </b>where XXXX corresponds to the participant ID. Participant IDs are listed in dataset demographics_incl.csv. The data in the Matlab formatted datasets result from preprocessing/formatting steps (see readme https://osf.io/fa5yp/). More details on the variables in each .mat file are provided in the document <b>DCNpaper_DataUpload-.docx.</b><i></i><b><br></b><b>MarkUpFile.docx </b>is a key explaining the EEG triggers found in the formatted data files (Triggers.matrix in each <b>Formatted_XXXX.3_40_preproc.mat</b>). Netstation triggers have a 4-character event code - and these are FXTN, BOIL, STIM, RESP and OFFS. They correspond to each trial event (FXTN = fixation onset, BOIL = boil; STIM = stimulus onset, RESP = response, and OFFS = stimulus offset).Each trigger also has keycode-keyvalue pairings (e.g., cohe = 10/30/50/75/100, dire = 0/1; corr = 0/1). When exporting the datafiles from Netstation to .raw files that were preprocessed in MATLAB, the authors converted these Netstation triggers into triggers with 4 digits that contain all of the information. These 4-digit triggers are found in Triggers.matrix in each Formatted_XXXX.3_40_preproc.mat file.<br>
DOI: 10.6084/m9.figshare.11926770.v1
title: Annotation

description: Annotations of transcript isoforms. Pfam protein domains along with E-values and GO terms via InterProScan.
DOI: 10.6084/m9.figshare.11926755
title: Abundance

description: Transcript isoform abundances via kallisto.
DOI: 10.6084/m9.figshare.11926722
title: Training and Verification datasets.zip

description: This file includes the inputs of CNN1 (the fringe images of 1000 scenes), the output of CNN1 (the numerator and denominator terms used to calculate the wrapped phases), the inputs of CNN2 (the fringe patterns of 1000 scenes captured by two cameras, and the reference plane information) and the outputs of CNN2 (the fringe orders corresponding to 1000 scenes).
DOI: 10.6084/m9.figshare.11926755.v1
title: Abundance

description: Transcript isoform abundances via kallisto.
DOI: 10.6084/m9.figshare.11926506
title: Metadata record for: A 12-Lead ECG database to identify origins of idiopathic ventricular arrhythmia containing 334 patients

description: This dataset contains key characteristics about the data described in the Data Descriptor A 12-Lead ECG database to identify origins of idiopathic ventricular arrhythmia containing 334 patients. <br> Contents: <br> 1. human readable metadata summary table in CSV format 2. machine readable metadata file in JSON format <br> <br> <br>
DOI: 10.6084/m9.figshare.11926506.v1
title: Metadata record for: A 12-Lead ECG database to identify origins of idiopathic ventricular arrhythmia containing 334 patients

description: This dataset contains key characteristics about the data described in the Data Descriptor A 12-Lead ECG database to identify origins of idiopathic ventricular arrhythmia containing 334 patients. <br> Contents: <br> 1. human readable metadata summary table in CSV format 2. machine readable metadata file in JSON format <br> <br> <br>
DOI: 10.6084/m9.figshare.11926284
title: Dynamic Bivariate Peak Over Threshold Model for Joint Tail Risk Dynamics of Financial Markets

description: We propose a novel dynamic bivariate peak over threshold (PoT) model to study the time-varying behavior of joint tail risk in financial markets. The proposed framework provides simultaneous modeling for dynamics of marginal and joint tail risk, and generalizes the existing tail risk literature from univariate dimension to multivariate dimension. We introduce a natural and interpretable tail connectedness measure and examine the dynamics of joint tail behavior of global stock markets: empirical evidence suggests markets from the same continent have time-varying and high-level joint tail risk, and tail connectedness increases during periods of crisis. We further enrich the tail risk literature by developing a novel portfolio optimization procedure based on bivariate joint tail risk minimization, which gives promising risk-rewarding performance in backtesting.
DOI: 10.6084/m9.figshare.11926284.v2
title: Dynamic Bivariate Peak Over Threshold Model for Joint Tail Risk Dynamics of Financial Markets

description: We propose a novel dynamic bivariate peak over threshold (PoT) model to study the time-varying behavior of joint tail risk in financial markets. The proposed framework provides simultaneous modeling for dynamics of marginal and joint tail risk, and generalizes the existing tail risk literature from univariate dimension to multivariate dimension. We introduce a natural and interpretable tail connectedness measure and examine the dynamics of joint tail behavior of global stock markets: empirical evidence suggests markets from the same continent have time-varying and high-level joint tail risk, and tail connectedness increases during periods of crisis. We further enrich the tail risk literature by developing a novel portfolio optimization procedure based on bivariate joint tail risk minimization, which gives promising risk-rewarding performance in backtesting.
DOI: 10.6084/m9.figshare.11926284.v1
title: Dynamic Bivariate Peak over Threshold Model for Joint Tail Risk Dynamics of Financial Markets*

description: We propose a novel dynamic bivariate peak over threshold (PoT) model to study the time-varying behavior of joint tail risk in financial markets. The proposed framework provides simultaneous modeling for dynamics of marginal and joint tail risk, and generalizes the existing tail risk literature from univariate dimension to multivariate dimension. We introduce a natural and interpretable tail connectedness measure and examine the dynamics of joint tail behavior of global stock markets: empirical evidence suggests markets from the same continent have time-varying and high-level joint tail risk, and tail connectedness increases during periods of crisis. We further enrich the tail risk literature by developing a novel portfolio optimization procedure based on bivariate joint tail risk minimization, which gives promising risk-rewarding performance in backtesting.
DOI: 10.6084/m9.figshare.11926272
title: Stata Analysis dta file for peri-urban paper on women's preferences for place of delivery in a peri-urban setting, Kenya

description: The dataset is the STATA dta file containing the analysis of the data for the study on eliciting preferences for place of delivery for peri-urban setting women in Kenya.
DOI: 10.6084/m9.figshare.11926278.v1
title: A Correction for Regression Discontinuity Designs with Group-Specific Mismeasurement of the Running Variable

description: When the running variable in a regression discontinuity (RD) design is measured with error, identification of the local average treatment effect of interest will typically fail. While the form of this measurement error varies across applications, in many cases the measurement error structure is heterogeneous across different groups of observations. We develop a novel measurement error correction procedure capable of addressing heterogeneous mismeasurement structures by leveraging auxiliary information. We also provide adjusted asymptotic variance and standard errors that take into consideration the variability introduced by the estimation of nuisance parameters, and honest confidence intervals that account for potential misspecification. Simulations provide evidence that the proposed procedure corrects the bias introduced by heterogeneous measurement error and achieves empirical coverage closer to nominal test size than “naive” alternatives. Two empirical illustrations demonstrate that correcting for measurement error can either reinforce the results of a study or provide a new empirical perspective on the data.
DOI: 10.6084/m9.figshare.11926137
title: HLA of SLE patients& HC data

description: We explored the association between <i>HLA-B</i> and <i>HLA-DR</i> genetic polymorphisms and clinical characteristics of systemic lupus erythematosus (SLE) in Yunnan Han patients in China. Data was collected from 116 Han patients from Yunnan province who were admitted to the Rheumatology and Immunology department of the First Affiliated Hospital of Kunming Medical University between September 2015 and September 2017. All patients were diagnosed with SLE according to the 2009 American College of Rheumatology criteria. Routine blood and urine tests, 24 hour urine protein quantification, complement level, autoantibodies, cytokines, lymphocytes, and SLE disease activity were recorded. Healthy Yunnan Han people (n = 118) were included as healthy controls (HCs). PCR was used to detect <i>HLA-B</i> and <i>HLA-DR</i> genotypes in patients and HCs, and allele and haplotype frequencies were compared and the correlation between susceptibility genes and SLE clinical features was explored. Thirty-four alleles were detected at the <i>HLA-DR </i>locus. The frequencies of the <i>HLA-DRB1*08:03 </i>and<i> </i><i>B*1</i><i>3</i><i>:</i><i>01</i> alleles were significantly higher in patients with SLE than in HCs (<i>P </i>= 0.012 and <i>P </i>= 0.040, for <i>DRB1*08:03</i> and <i>B*1</i><i>3</i><i>:</i><i>01</i>, respectively). Conversely, 24 hour urine protein was significantly lower in the <i> HLA-DRB1*08:03 </i>positive group than in the <i>HLA-DRB1*08:03</i> negative group (1.93 ± 2.830 vs. 3.55 ± 4.556, <i>P </i>= 0.03). <i>HLA-DRB1*11:01</i> allele frequency was significantly lower in patients with SLE than in HCs (0.44 % vs. 4.66%, <i>P </i>= 0.006, OR 0.091, 95% CI: 0.012–0.710). Fifty-three alleles were detected at the<i> HLA-B </i>locus. The <i>B*46:01</i> allele frequency was significantly lower in patients with SLE than in HCs (<i>P </i>= 0.041). The frequency of <i>HLA-B/DR </i>haplotype <i>B*13:01/DR*15:01</i> was higher in patients with SLE than in HCs, but the difference was not statistically significant (<i>P </i>= 0.05). Our results indicate that, in patients of Han ethnicity in Yunnan province in China, SLE is related to the <i>HLA-DRB1*08:03</i> and <i>HLA-B*</i><i>13</i><i>:</i><i>01</i> alleles, and that alleles <i>HLA-DRB1*11:01</i><i> </i>and <i>HLA-B*46: 01</i> may play a protective role. Additionally, <i>HLA-D</i><i>RB1*08:03</i> may be related to SLE with renal involvement. However, the incidence of SLE is related to certain <i>HLA </i>gene combinations. Those alleles may be considered genetic markers of SLE susceptibility in Yunnan Han patients.The research protocol was approved by the Institutional Review Board of Kunming Medical University, Yunnan Province, PR China (ClinicalTrials.gov: NCT00703742).<br>
DOI: 10.6084/m9.figshare.11926137.v2
title: HLA of SLE patients& HC data

description: We explored the association between <i>HLA-B</i> and <i>HLA-DR</i> genetic polymorphisms and clinical characteristics of systemic lupus erythematosus (SLE) in Yunnan Han patients in China. Data was collected from 116 Han patients from Yunnan province who were admitted to the Rheumatology and Immunology department of the First Affiliated Hospital of Kunming Medical University between September 2015 and September 2017. All patients were diagnosed with SLE according to the 2009 American College of Rheumatology criteria. Routine blood and urine tests, 24 hour urine protein quantification, complement level, autoantibodies, cytokines, lymphocytes, and SLE disease activity were recorded. Healthy Yunnan Han people (n = 118) were included as healthy controls (HCs). PCR was used to detect <i>HLA-B</i> and <i>HLA-DR</i> genotypes in patients and HCs, and allele and haplotype frequencies were compared and the correlation between susceptibility genes and SLE clinical features was explored. Thirty-four alleles were detected at the <i>HLA-DR </i>locus. The frequencies of the <i>HLA-DRB1*08:03 </i>and<i> </i><i>B*1</i><i>3</i><i>:</i><i>01</i> alleles were significantly higher in patients with SLE than in HCs (<i>P </i>= 0.012 and <i>P </i>= 0.040, for <i>DRB1*08:03</i> and <i>B*1</i><i>3</i><i>:</i><i>01</i>, respectively). Conversely, 24 hour urine protein was significantly lower in the <i> HLA-DRB1*08:03 </i>positive group than in the <i>HLA-DRB1*08:03</i> negative group (1.93 ± 2.830 vs. 3.55 ± 4.556, <i>P </i>= 0.03). <i>HLA-DRB1*11:01</i> allele frequency was significantly lower in patients with SLE than in HCs (0.44 % vs. 4.66%, <i>P </i>= 0.006, OR 0.091, 95% CI: 0.012–0.710). Fifty-three alleles were detected at the<i> HLA-B </i>locus. The <i>B*46:01</i> allele frequency was significantly lower in patients with SLE than in HCs (<i>P </i>= 0.041). The frequency of <i>HLA-B/DR </i>haplotype <i>B*13:01/DR*15:01</i> was higher in patients with SLE than in HCs, but the difference was not statistically significant (<i>P </i>= 0.05). Our results indicate that, in patients of Han ethnicity in Yunnan province in China, SLE is related to the <i>HLA-DRB1*08:03</i> and <i>HLA-B*</i><i>13</i><i>:</i><i>01</i> alleles, and that alleles <i>HLA-DRB1*11:01</i><i> </i>and <i>HLA-B*46: 01</i> may play a protective role. Additionally, <i>HLA-D</i><i>RB1*08:03</i> may be related to SLE with renal involvement. However, the incidence of SLE is related to certain <i>HLA </i>gene combinations. Those alleles may be considered genetic markers of SLE susceptibility in Yunnan Han patients.The research protocol was approved by the Institutional Review Board of Kunming Medical University, Yunnan Province, PR China (ClinicalTrials.gov: NCT00703742).<br>
DOI: 10.6084/m9.figshare.11926137.v1
title: HLA of SLE patients& HC data

description: We explored the association between <i>HLA-B</i> and <i>HLA-DR</i> genetic polymorphisms and clinical characteristics of systemic lupus erythematosus (SLE) in Yunnan Han patients in China. Data was collected from 116 Han patients from Yunnan province who were admitted to the Rheumatology and Immunology department of the First Affiliated Hospital of Kunming Medical University between September 2015 and September 2017. All patients were diagnosed with SLE according to the 2009 American College of Rheumatology criteria. Routine blood and urine tests, 24 hour urine protein quantification, complement level, autoantibodies, cytokines, lymphocytes, and SLE disease activity were recorded. Healthy Yunnan Han people (n = 118) were included as healthy controls (HCs). PCR was used to detect <i>HLA-B</i> and <i>HLA-DR</i> genotypes in patients and HCs, and allele and haplotype frequencies were compared and the correlation between susceptibility genes and SLE clinical features was explored. Thirty-four alleles were detected at the <i>HLA-DR </i>locus. The frequencies of the <i>HLA-DRB1*08:03 </i>and<i> </i><i>B*1</i><i>3</i><i>:</i><i>01</i> alleles were significantly higher in patients with SLE than in HCs (<i>P </i>= 0.012 and <i>P </i>= 0.040, for <i>DRB1*08:03</i> and <i>B*1</i><i>3</i><i>:</i><i>01</i>, respectively). Conversely, 24 hour urine protein was significantly lower in the <i> HLA-DRB1*08:03 </i>positive group than in the <i>HLA-DRB1*08:03</i> negative group (1.93 ± 2.830 vs. 3.55 ± 4.556, <i>P </i>= 0.03). <i>HLA-DRB1*11:01</i> allele frequency was significantly lower in patients with SLE than in HCs (0.44 % vs. 4.66%, <i>P </i>= 0.006, OR 0.091, 95% CI: 0.012–0.710). Fifty-three alleles were detected at the<i> HLA-B </i>locus. The <i>B*46:01</i> allele frequency was significantly lower in patients with SLE than in HCs (<i>P </i>= 0.041). The frequency of <i>HLA-B/DR </i>haplotype <i>B*13:01/DR*15:01</i> was higher in patients with SLE than in HCs, but the difference was not statistically significant (<i>P </i>= 0.05). Our results indicate that, in patients of Han ethnicity in Yunnan province in China, SLE is related to the <i>HLA-DRB1*08:03</i> and <i>HLA-B*</i><i>13</i><i>:</i><i>01</i> alleles, and that alleles <i>HLA-DRB1*11:01</i><i> </i>and <i>HLA-B*46: 01</i> may play a protective role. Additionally, <i>HLA-D</i><i>RB1*08:03</i> may be related to SLE with renal involvement. However, the incidence of SLE is related to certain <i>HLA </i>gene combinations. Those alleles may be considered genetic markers of SLE susceptibility in Yunnan Han patients.The research protocol was approved by the Institutional Review Board of Kunming Medical University, Yunnan Province, PR China (ClinicalTrials.gov: NCT00703742).<br>
DOI: 10.6084/m9.figshare.11926101.v1
title: Provenance record of a rift basin and its implications: U-Pb ages of detrital zircons from the Beibuwan Basin, South China Sea

description: This supporting information provides the LA-ICP-MS analytical condition and geochronological data. The 16 samples are derived from Hainan Island and Beibuwan Basin, South China Sea. <br>
DOI: 10.6084/m9.figshare.11925999
title: Supplementary Material for: Targeting Galectin-1 by Aflibercept Strongly Enhances Its Antitumor Effect in Neuroendocrine Carcinomas

description: <b><i>Background:</i></b> Galectin-1 (Gal-1) plays major roles in cancer by modulating different processes leading to tumor development and progression. In the last years, it has been suggested as a promising target for anticancer therapy. Recently, aflibercept has shown high affinity for Gal-1. Here, we investigated how aflibercept could exert its antitumor activity via Gal-1-driven pathways in neuroendocrine carcinomas (NECs). <b><i>Methods and Results:</i></b> NEC tumor xenografts were used to assess the effect of aflibercept on Gal-1 functions. Aflibercept induced a significant reduction of Gal-1 at epithelial, stromal, and extracellular localizations in lung NEC, whereas this was not observed in colon NECs, which displayed low expression of Gal-1. Additionally, aflibercept significantly reduced p-VEGFR2 protein, extracellular matrix remodeling, epithelial-mesenchymal transition, and activation of cancer-associated fibroblast hampering cell invasion in lung NEC but not in colon NEC. Gal-1 screening in human NECs confirmed that pulmonary and pancreatic tumors displayed higher levels of Gal-1 than colon NECs, becoming good candidates to benefit from aflibercept treatment. <b><i>Conclusions:</i></b> The lack of validated predictive markers of aflibercept is a weakness for guaranteeing the best treatment management with this drug. This work provides new mechanistic insight of aflibercept depending on Gal-1. Thus, in tumors overexpressing Gal-1, aflibercept has not only an antiangiogenic effect but also prevents Gal-1-mediated tumor-stroma cross talk. The stronger aflibercept effect in tumors with high levels of Gal-1 points out this protein as a molecular marker to predict the efficacy of this agent not only for NECs but also for other tumors with high levels of this protein.
DOI: 10.6084/m9.figshare.11925999.v1
title: Supplementary Material for: Targeting Galectin-1 by Aflibercept Strongly Enhances Its Antitumor Effect in Neuroendocrine Carcinomas

description: <b><i>Background:</i></b> Galectin-1 (Gal-1) plays major roles in cancer by modulating different processes leading to tumor development and progression. In the last years, it has been suggested as a promising target for anticancer therapy. Recently, aflibercept has shown high affinity for Gal-1. Here, we investigated how aflibercept could exert its antitumor activity via Gal-1-driven pathways in neuroendocrine carcinomas (NECs). <b><i>Methods and Results:</i></b> NEC tumor xenografts were used to assess the effect of aflibercept on Gal-1 functions. Aflibercept induced a significant reduction of Gal-1 at epithelial, stromal, and extracellular localizations in lung NEC, whereas this was not observed in colon NECs, which displayed low expression of Gal-1. Additionally, aflibercept significantly reduced p-VEGFR2 protein, extracellular matrix remodeling, epithelial-mesenchymal transition, and activation of cancer-associated fibroblast hampering cell invasion in lung NEC but not in colon NEC. Gal-1 screening in human NECs confirmed that pulmonary and pancreatic tumors displayed higher levels of Gal-1 than colon NECs, becoming good candidates to benefit from aflibercept treatment. <b><i>Conclusions:</i></b> The lack of validated predictive markers of aflibercept is a weakness for guaranteeing the best treatment management with this drug. This work provides new mechanistic insight of aflibercept depending on Gal-1. Thus, in tumors overexpressing Gal-1, aflibercept has not only an antiangiogenic effect but also prevents Gal-1-mediated tumor-stroma cross talk. The stronger aflibercept effect in tumors with high levels of Gal-1 points out this protein as a molecular marker to predict the efficacy of this agent not only for NECs but also for other tumors with high levels of this protein.